



**BIOFIL CHEMICALS & PHARMACEUTICALS LTD.**  
Regd. Office : 11/12, Sector-E, Sanwer Road, Industrial Area, Indore - 452 015. Fax : 0731-2723017  
Tel. : 0731-2723016, 4066216 E-mail : biofilchemicals@yahoo.com / bcplcompliance@gmail.com  
Factory : Plot No. 8, Sector - IV, Kheda Industrial Area, Pithampur Distt. Dhar (M.P.)  
Admn. Office : B-12/B, Industrial Estate, Pologround, Indore - 452 015 (M.P.)  
Tel. : 0731-2426700, 2426718, 2524003, Fax : 0731-2426726 • CIN : L24233MP1985PLC002709

Date: 04/08/2017

To,  
The Company Secretary,  
Corporate Compliance Department  
The National Stock Exchange of India Limited  
Bandra Kurla Complex, Mumbai

To,  
The Company Secretary  
Corporate Compliance Department  
BSE Limited  
Dalal Street, P.J. Tower, Mumbai

Sub: Approval of Un-audited Financial Result for the quarter ended on 30<sup>th</sup> June, 2017 and Limited Review Report thereon pursuant to regulation 33 of SEBI (LODR) 2015  
Ref- (BSE Scrip Code: 524396; NSE Scrip Id: BIOFILCHEM; ISIN No. INE829A01014)

Dear Sir/Madam

With reference to the above-mentioned subject in meeting of the Board of the Directors of the Company held on today 4<sup>th</sup> August, 2017, has approved the Un-audited Financial Result for the quarter ended on 30<sup>th</sup> June, 2017 and Limited Review Report thereon.

Copy of un-audited financial result along with Limited Review Report is enclosed with this letter and copy of the same is also available at website [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and on website of the Company. i.e [www.biofilgroup.net](http://www.biofilgroup.net).

This is for your information and record.

Thanking you,

Yours Faithfully  
For Biofil Chemicals and Pharmaceuticals Limited

Ramesh Shah  
Managing Director  
(DIN No. 00028819)




Un-Audited Financial Results of Quarter and Year Ended of JUNE. 2017  
30-06-2017 of M/s. Biofil Chemicals & Pharmaceuticals Limited  
11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)

CIN L24233MP1985PLC002709

UN- AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 30th June , 2017

( Amount in Lakhs except EPS)

Statement of Standalone Unaudited Financial Results for the Quarter & Year ended 30th June 2017						
	Particulars	3 months quarter ended 30/06/2017	3 Months Quarter Ended 31/03/2017	3 months quarter ended 30/06/2016	Audited for the year ended March 31 2017	
		Un- audited	Audited (Refer Note 3)	Un-audited	Audited	
1	(a) Income From Operation	706.35	625.66	32.93	1347.74	
	(b) Other Income	0.32	8.04	-	11.49	
	<b>Total Revenue</b>	<b>706.67</b>	<b>633.70</b>	<b>32.93</b>	<b>1359.23</b>	
2	<b>Expenses</b>					
	(a) Cost of materials consumed	13.52	30.22	17.19	90.41	
	(b) Purchases of stock-in-trade	663.75	330.93	4.80	762.02	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2.20)	16.03	(11.25)	(1.32)	
	(d) Employee benefits expense	5.69	25.40	4.57	53.22	
	(e) Finance Cost	3.75	5.11	3.75	16.36	
	(f) Depreciation and Amortisation Expense	7.11	8.85	6.53	28.42	
	(g) Other expenses	5.28	65.23	4.82	179.08	
	<b>Total expenses</b>	<b>696.91</b>	<b>481.78</b>	<b>30.40</b>	<b>1128.19</b>	
3	<b>Profit (Loss) before tax (1-2)</b>	<b>9.76</b>	<b>151.93</b>	<b>2.53</b>	<b>231.04</b>	
4	<b>Tax expense:</b>					
	Current tax		51.62	-	51.62	
	Deferred tax Credit/(Charge)					
5	<b>Profit (Loss) before tax (3-4)</b>	<b>9.76</b>	<b>100.30</b>	<b>2.53</b>	<b>179.42</b>	
	Other Comprehensive Income	-	-	-	-	
6	a) Items that will not be reclassified to Profit or Loss (Consisting of re-measurement of net defined benefit liability/asset)	-	-	-	-	
	b) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	
	c) Other Comprehensive Income (net of tax) 6a± 6b)	-	-	-	-	
7	<b>Total Comprehensive Income</b>	<b>9.76</b>	<b>100.30</b>	<b>2.53</b>	<b>179.42</b>	
8	<b>Paid-Up equity share capital (face value of Rs 5/- each)</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	<b>1627.38</b>	
9	<b>Other Equity excluding Revaluation Reserve as per balance Sheet</b>				<b>376.21</b>	
10	<b>Earnings per equity shares:</b>					
	(1) Basic (Rs)	0.06	0.62	0.02	1.10	
	(2) Diluted (Rs)	0.06	0.62	0.02	1.10	



1. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.

2. The standalone unaudited financial results of Biofil Chemicals & Pharmaceuticals Ltd, ("the company" for the quarter ended June 30, 2017 were reviewed by the Audit committee and approved by the Board of Directors at their meeting held on August 4, 2017.

3. The Limited Review of the financial Results of the Quarter ended 30th June 2017 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements Regulations 2015, has been carried out by the Statutory Auditors.

4. The Ind AS compliant corresponding figures for the quarter ended June 30 2016, have not been subject to review or audit. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.

5. The Company has reported segment wise information as per Accounting Standard (AS-17). The Operations of the company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments

1. Pharma Product
2. Chemicals Division
3. Plastic Division

6. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below.

Description	3 Months Ended 30/06/2016	3 Months Ended 31/03/2017	Audited for the year ended March 31 2017
	Un-audited	Audited	Audited
<b>Total Income From Operation</b>	<b>32.93</b>	<b>625.66</b>	<b>1347.74</b>
Net profit/(Loss) (before tax, exceptional and / or Extraordinary items)	2.53	151.93	231.04
Net Profit/ (Loss) before tax (after exceptional and /or extraordinary items)	2.53	151.93	231.04
Net Profit/ (Loss) After tax (after exceptional and /or extraordinary items)	2.53	100.30	179.42
Total Comprehensive Income / (Loss) (Comprising of Profit/(Loss) for the period after tax and other Comprehensive Income after tax)	2.53	100.30	179.42
Paid up equity shares capital (Rs 10/- each)	1627.38	1627.38	1627.38
Other Equity excluding revaluation reserves as shown in the audited balance sheet of the previous year			376.21
Earning per share (Face value Rs 10 each)			
* Not annulised			
Basic	0.02	0.62	1.10
Diluted	0.02	0.62	1.10

7. The aforesaid audited financial Results will be uploaded on the Company's website [www.biofilgroup.net](http://www.biofilgroup.net) and will also be available on the websites of the Stock exchanges i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) for the benefit of shareholders and investors

Date : 4th August 2017  
Place : Indore

FOR Biofil Chemicals & Pharmaceuticals Limited  
  
**RAMESH SHAH**  
 MANAGING DIRECTOR  
 (DIN : 00028819)



**BIOFIL CHEMICALS & PHARMACEUTICALS LTD.**  
**CIN NO. L24233MP1985PLC002709**

Segmentwise Revenue, Results an Capital Employed for year ended 30th June 2017

( Amount in Lakhs)

S.No.	Segment Revenue	Quarter Ended			Year Ended
		June 30 ,	March 31,	June 30 ,	31 March
		2017	2017	2016	2017
		Reviewed	Audited	Reviewed	Audited
1	<b>Segment Revenue</b>	679.30	662.49	6.16	1205.08
	Pharma Unit	24.21	41.23	25.63	139.077
	Chemicals Division	2.84	0.28	0.00	1.281
	Plastic Division	0.32	(70.30)	1.13	13.794
	Other	706.67	633.70	32.93	1359.23
	<b>Gross Turnover</b>				
2	<b>Segment Results</b>	15.71	156.00	4.44	252.24
	Pharma Unit	(1.29)	(29.57)	5.53	(21.46)
	Chemicals Division	(0.91)	6.72	(3.69)	(7.26)
	Plastic Division	0.00	19.84	0.00	19.84
	Other				
	<b>Total Segment Profit Before Tax</b>	<b>13.51</b>	<b>152.99</b>	<b>6.28</b>	<b>243.36</b>
	Interest Income	0.00	2.69	0.00	2.69
	Interest Expenses	3.75	3.76	3.75	15.01
	Other Unallocable Income net of Expenditure				
	<b>Profit Before Tax</b>	<b>9.76</b>	<b>151.92</b>	<b>2.53</b>	<b>231.04</b>
	Provision for current tax	0.00	50.00	0.00	50.000
	Item Related Earlier Year	0.00	1.62	0.00	1.622
	<b>Profit After Tax</b>	<b>9.76</b>	<b>100.30</b>	<b>2.53</b>	<b>179.42</b>
3	<b>Capital Employed</b>				
	<b>Segment Assets (A)</b>				
	Pharma Division	1896.85	1309.64	1240.02	1309.64
	Chemicals Division	806.17	802.50	763.73	802.50
	Plastic Division	70.47	71.90	84.89	71.90
	Other				
	<b>Total (A)</b>	<b>2773.50</b>	<b>2184.04</b>	<b>2088.64</b>	<b>2184.04</b>
	<b>Segment Liabilities (B)</b>				
	Pharma Division	1299.62	703.01	848.30	703.01
	Chemicals Division	77.41	66.53	32.15	66.53
	Plastic Division	145.51	144.85	138.73	144.85
	Other				
	<b>Total (B)</b>	<b>1522.54</b>	<b>914.38</b>	<b>1019.18</b>	<b>914.38</b>
	<b>Total Capital Employed</b>	<b>1250.96</b>	<b>1269.65</b>	<b>1069.45</b>	<b>1269.65</b>

DATE : 04th August 2017  
 PLACE : INDORE

BIOFIL CHEMICALS & PHARMACEUTICALS LTD.



**RAMESH SHAH**  
**MANAGING DIRECTOR**  
 DIN: 00028819





**S.N. Gadiya & Co.**  
(Chartered Accountants)

**Satya Narayan Gadiya**  
F.C.A., B. Com.  
Mob. : 9301503126

**Limited Review Report**

The Board of Directors,  
M/S Biofil Chemicals And Pharmaceuticals Limited  
11/12, Sector E Sanwer Road  
Industrial Area  
Indore452015 -M.P.

We have reviewed the accompanying statement of unaudited financial results (the "Statement") of Biofil Chemicals and Pharmaceuticals Limited ("the Company") for the quarter ended 30<sup>th</sup> June 2017 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that figures for the corresponding quarter ended 30<sup>th</sup> June 2017 including the reconciliation of net profit under Ind AS of the corresponding quarter with net profit reported under previous GAAP, as included in the Statement have been approved by the Board of Directors. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, SEBI Circular CIF/CFD/CMD/15/2015 dated 30<sup>th</sup> November 2015, and CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July 2016, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in accordance with the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.N. Gadiya & Co.  
Chartered Accountants  
FRN: 002052C

S.N. Gadiya  
Proprietor  
M. No.071229



Date : 04.08.2017  
Place:-Indore

241, Apollo Tower, 2, M.G. Road, Indore-1 Ph. : 07314069030  
Resi. : 15, Textile Clerk Colony, Indore-10 Ph. : 07314031266  
E-mail : satya\_mewar@rediffmail.com